Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9410564 | 0.84 | MAOB (0.49) | CCNA2CDK2FLT3CCNA1EGFR | |
| SCHEMBL29135561 | 0.80 | GAA (0.45) | EGFRSRCMEN1KMT2AALDH1A1 | |
| SCHEMBL9587428 | 0.80 | YTHDC1 (0.49) | FLT3EGFRSRCNPC1RAB9A | |
| SCHEMBL9410581 | 0.80 | NPC1 (0.51) | FLT3EGFRSRCNPC1RAB9A | |
| SCHEMBL1642680 | 0.79 | KDM4E (0.42) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL9598556 | 0.76 | ALDH1A1 (0.46) | RAB9ASMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL1642667 | 0.74 | ALDH1A1 (0.46) | EGFRSRCSMN1; SMN2LMNAMEN1 | |
| SCHEMBL5473200 | 0.74 | PBRM1 (0.46) | LMNAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4919214 | 0.73 | NR4A2 (0.50) | LMNAMEN1KMT2APTPN1ALDH1A1 | |
| SCHEMBL27392340 | 0.70 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393801-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2185541-B1 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-28 | — | — | EP | disclosed |
| US-8853406-B2 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| EP-2001868-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-17 | — | — | EP | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8377961-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8232298-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | LACRAMPE JEAN FERNAND ARMAND (FR) | 2012-03-22 | — | — | US | disclosed |
| US-8088795-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| EP-2185541-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| US-20090149493-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN-CILAG (FR) | 2009-06-11 | — | — | US | disclosed |
| WO-2009019274-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-12 | — | — | WO | disclosed |
| EP-2001868-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1999126-A1 | CYCLIC-ALKYLAMINEDERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2008-12-10 | — | — | EP | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007107545-A1 | CYCLIC-ALKYLAMINEDERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107543-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1809622-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006032631-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | CCNA2 22/4885CDK2 68/4885FLT3 397/4885 |
| US-20090149493-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | CCNA2 26/4885CDK2 23/4885FLT3 1376/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | CCNA2 69/4885CDK2 36/4885FLT3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.